國家衛生研究院 NHRI:Item 3990099045/4444
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12340/13424 (92%)
造訪人次 : 2003469      線上人數 : 448
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版
    國家衛生研究院 NHRI > 癌症研究所 > 其他 > 期刊論文 >  Item 3990099045/4444


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4444


    題名: The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: A preliminary report
    其他題名: 皮下注射基因工程合成人類紅血球生長素對於惡性腫瘤病人化學治療所併發續發性貧血療效之初步評估
    作者: Chiou, TJ;Chim, YS;Wei, CH;Hsieh, RK;Chen, PM
    貢獻者: National Institute of Cancer Research
    摘要: Background. Chemotherapy-related anemia in cancer patients is often encountered in clinical practice. It can reduce patient's compliance and tolerance to continuing chemotherapy. The mechanism of anemia may be ascribed to either decreasing serum EPO concentration or reducing sensitivity of EPO. Exogenous supply of EPO has shown to be effective in control of cancer- related anemia in early reports. This study preliminarily explored the efficacy and safety of r-HuEPO for cancer patients with anemia during the cytotoxic chemotherapy period in Taiwan. Methods. Sixteen cancer patients receiving cyclic chemotherapy with anemia (Hgb ? 10.5 g/dl) and without other systemic organ dysfunction, cerebral metastasis, uncontrolled hypertension, or presence of anemia attributable to causes other than cancer and chemotherapy entered the study. All patients received r-HuEPO 150 u/kg subcutaneous injection tiw for a total of 16 weeks. The efficacy determinations was based on the effect of r-HuEPO on hematological parameters, transfusion requirements, quality of life assessment, and physician's global assessment. Safety was assessed based on clinical laboratory tests, vital sign measurements and the incidence and severity of adverse experiences. Results. There were no changes of WBC and platelet count in 4, 8, 12 and 16 weeks of r-HuEPO therapy. The mean hemoglobin values at baseline, week 4, 8, 12, and 16 were 9.2±1.0 g/dl, 11.4±0.9 g/dl, 11.6±1.8 g/dl, 11.8±1.8 g/dl, and 12.2±2.3 g/dl, respectively (p < 0.001). The mean hematocrit values at baseline, week 4, 8, 12, and 16 were 28.3±3.4%, 36.0±2.8%, 36.3±5.7%, 37.8±6.0%, and 40.1±7.1%, respectively (p < 0.0005). The use of r-HuEPO had the marginal effect on the increase of patient's energy and activity. No adverse impacts on patient's vital signs were noted except 2 incidences of systolic hypertension and one episode of diastolic hypertension in the week 4. Conclusions. Subcutaneous injection of r-HuEPO at the dose of 150 u/kg tiw was safe and effective in increasing patient's hematocrit and RBC mass, and decreasing their blood transfusion requirement. Whether the current dosage of 150 u/kg tiw is the optimal treatment for chemotherapy-related anemia still needs further study.
    日期: 1997
    關聯: Chinese Medical Journal (Taipei). 1997;60(5):229-235.
    Link to: http://www.ncbi.nlm.nih.gov/pubmed/9509677
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0031429787
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP0031429787.pdf2079KbAdobe PDF258檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋